Update on the Psoriasis Treatment by Biologics and Standard Systemic Drugs
Authors:
N. Benáková 1; J. Štork 2
Authors‘ workplace:
Dermatologická ordinace NZZ Praha
vedoucí lékař MUDr. R. Klubal
1; Dermatovenerologická klinika 1. LF UK Praha a VFN
přednosta prof. MUDr. J. Štork, CSc.
2
Published in:
Čes-slov Derm, 83, 2008, No. 4, p. 191-202
Category:
Innovations in Medicine
Overview
Authors give an updated review of recent knowledge regarding the pathogenesis of psoriasis and the development of new systemic drugs. Further information about comorbidities and their significance for praxis is provided. Recommended indication criteria of the Czech Society of Dermatology and related issues are mentioned. Efficacy, switching therapy to another biologic drug and combined treatment are discussed. Regarding safety of the treatment they introduce new specifications and recommendations for clinical and laboratory patient monitoring. The article includes basic information about a biological drug, adalimumab, recently implemented in the treatment of psoriasis. In conclusion, the significance of biologics is summarized as very promising drugs, the development of which led to better understanding of psoriasis pathogenesis and, moreover, indirectly increased the use of the standard systemic antipsoriatics.
Key words:
psoriasis – etiopathogenesis – new drugs – comorbidities – biologic treatment recommendations update
Sources
1. BARCLAY, L. Severe but not mild psoriasis may increase mortality by 50%. Arch Dermatol, 2007,143, p. 1493-1499.
2. BEGLINGER, C. et al.. Screening for tuberculosis infection before initiation of anti-TNF therapy. SWISS Med Wkly, 2007, 137, p. 621-622.
3. BENÁKOVÁ, N., ŠTORK, J. Léčba psoriázy biologiky. Čes-slov Derm, 2006, 81 (4) Suppl.,S1-11.
4. BENÁKOVÁ, N., ETTLER, K., ŠTORK, J., VAŠKŮ, V. Psoriáza nejen pro praxi. Triton 2007. 190 s.
5. BENÁKOVÁ, N. Komorbidita psoriázy. Referátový výběr, Speciál Psoriáza 2008, s. 4-6.
6. BREZINSCHEK, HP., HOFSTAETTER, T., LEEB, BF. et al. Immunization of patients with rheumatoid arthritis with antitumor necrosis factor alpha therapy and methotrexat.Curr Opin Rheumatol, 2008, 20(3), p. 295-9.
7. BROADLEY, SA. et al. Autoimmune disease in first degree relatives of patients with mutiple sclerosis: a UK survey. J Am Acad Dermatol, 2000, 23, p. 1102-1111.
8. CARTER, JD., GERARD, HC.,HUDSON, AP. Psoriasiform lesions induced by TNF antagonists: a skin-deep medical conundrum. Ann Rheum Dis, 2008 (Feb 25)- on line early.
9. COHEN, AD., DREIHER, I., SHAPIRO, Y. et al. Psoriasis and diabetes: a population-based cross-sectional study. JEADV, 2008, 22, p. 585-589.
10. DRIESSEN, RJ., BEREND, MM., BOEZEMAN, JB. et al. Psoriasis treatment with etanercept and efalizumab: clinical strategies influencing treatment outcome. Br J Dermatol, 2008, 158, p. 1098-1108.
11. GELFAND, JM., TROXEL, AB., LEWIS, JD. et al. The risk of mortality in patients with psoriasis. Arch Dermatol, 2007, 143(12), p.1493-1499.
12. GISONDI, P., TESSARI, G., CONTI, A. et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol, 2007, 157(1), p. 68-73.
13. G ISONDI, P. et al. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis. Br J Dermatol, 2008, 158, p.134-149.
14. GORDON, KB,. LANGLEY, RG., LEONARDI, C. et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open label extension study. JAAD, 2006, 55 (4), p. 598-606.
15. HARRISON, MJ., DIXON, WG.,WATSON, KD. et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-TNFα therapy. Results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis, 2008 (Apr 2)- on line early.
16. HASHMI, S., ZENG, QT. Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron Artery Dis, 2006, 17(8), p. 699-706.
17. HERRON, M., HINCKLEY, M., HOFFMAN, MS. et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol, 2005 141(12), p. 1527-34.
18. KIMBALL, AB. et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody in the treatment of moderate to severe chronic plaque psoriasis. Arch Dermatol, 2008, 144 (2), p. 200-207.
19. KIMBALL, AB. et al. Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases 2001-2002. Dermatology, 2008, 217, p. 27-37.
20. Kolektiv autorů: Léčba psoriázy efalizumabem. Čes-slov Derm, 2008, 83 (1), Suppl. S3- S35.
21. KOUROSH, AS., MINER, A., MENTER, A. Psoriasis as the marker of underlying systemic disease. Skin Therapy Lett, 2008,13 (1), p.1-5.
22. LANGLEY, RG. et al. Adalimumab efficiacy in treatment of moderate to severe chronic plaque psoriasis is sustained through 60 weeks, with an acceptable safety profile. J Invest Dermatol, 2007, 127, p. 1820.
23. LEONARDI, C., MENTER, A., HAMILTON, T. et al. Efalizumab: results of a 3-year dosing study for the long term control of psoriasis. Br J Dermatol, 2008, 158, p. 1107-1116.
24. MAREK, J. Hormony, hormonální léčba a složky metabolického syndromu. Lék Listy, 2007,17, s. 24-26.
25. MENTER, A., FELDMAN, SR,, WEINSTEIN, GD et al. A randomized comparison of continuous vs. intermitent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol, 2007, 56 (1), p. 31-35.
26. MENTER, A., GOTTLIEB, A., FELDMAN, SR. et al. Guidelines of care for the management of psoriasis and psoriatic artritis. J Am Acad Dermatol, 2008, 58 (5), p. 826-850.
27. ORMEROD, A. Assessing the long-term safety of biologics for psoriasis. Dermatol Practice, 2008, 16 (1), p.8-11.
28. PALLER, AS. et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med, 2008, 358, p. 241-251.
29. PEARCE, DJ., FELDMAN, SR. Update on infliximab: an intravenous biologic therapy for psoriasis. Expert Res Dermatol, 2007, 2(6), p. 707-713.
30. RAZA, N. et al. Detection of subclinical joint involvement in psoriasis with bone scintigraphy and its response to oral methotrexate. Clin Exp Dermatol, 2008, 33 (1), p. 70-73.
31. ROSMARIN, D. et al.: Patch testing a patient with allergic contact hand dermatitis who is taking infliximab. J Am Acad Dermatol. 2008 (May 9) – on line early.
32. SAAD, AA., SYMMONS, DP., NOYCE, PR. et al. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol, 2008 (Mar 15) - v tisku.
33. SEURAT, J. et al. Champion phase III trial results: Adalimumab efficiacy and safety compared with methotrexate and placebo in patients moderate to severe psoriasis. Poster P035.165 na 16. kongresu EADV Vídeň 2007.
34. SHELLING, ML., FEDERMAN, DG., PRODANOVICH, S. et al. Psoriasis and vascular disease: an unsolved mystery. Am J Med, 2008, 121 (5), p. 360-365.
35. SOMMER, DM., JENISCH, S., SUCHAN, M. et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res, 2007, 298 (7), p. 321-8.
36. STERRY, W., STROBER, BE., MENTER, A. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol, 2007, 157 (4), p. 649-655.
37. STINGL et al. Raptiva: Pan-Europen Experience in psoriasis patients. Br J Dermatol, 2007, 150, Suppl. 2, p. 1-29.
38. ŠTORK, J. Systémová léčba psoriázy – kvantitativní výzkum mezi dermatology. Čs Derm, 2007, 82 (6) s. 352-5.
39. TZU, J. KERDEL, F. From conventional to cutting edge: the new era of biologics in treatment of psoriasis. Dermatol Ther, 2008, 21, p. 131-141.
40. VAN DE KERKHOF, P. Etanercept 50 mg once weekly is effective and well tolerated in patients with moderate to severe psoriasis. Poster na Fall Clinical Dermatology conference, October 2007, Las Vegas.
43. VANTUCHOVÁ, Y., SVOBODOVÁ, E. Naše zkušenosti s biologickou léčbou psoriázy. Referátový výběr z dermatovenerologie, 2008, Speciál I, s. 35-42.
44. VOOLENHOVEN, RF. Switching between anti-tumour necrosis factors: trying to get a nadle on a complex issue. Ann Rheum Dis, 2007, 66, p. 849-851.
46. WANG, Y.et al. Psoriasis is associated with increased levels of serum leptin. Br J Dermatol, 2008,158, p. 1134-35.
47. WAYNE, PG.: Importance of screening for comorbidities in psoriasis patients. Expert Rev Dermatol, 2008, 3 (2), p. 133-135.
48. WOLLINA, U. et al. Tumor necrosis factor-α inhibitor-induced psoriasis or psoriasiform exanthema: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol, 2008, 9 (1), p.1-14.
49. ZABA, LC., CARDINALE, I., GILLEAUDEA, P. et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med, 2007, 204 (13), p. 3183-3194.
50. Přednášky z 2. mezinárodního kongresu o psoriáze, Paříž, 21.-24.VI. 2007. JEADV 2007, 21, Suppl. 1, 69 s.
51. Přednášky z 66. Annual Meeting of American Academy of Dermatovenerology San Antonio, 1.-5. II. 2008.
Labels
Dermatology & STDs Paediatric dermatology & STDsArticle was published in
Czech-Slovak Dermatology
2008 Issue 4
Most read in this issue
- Newer Childhood Viral Exanthemas – Overview
- Case Study of Patient with Blastic NK-cell Lymphoma also Termed CD4+/CD56+ Hematodermic Neoplasia or Early Plasmocytoid Leukaemia/ Dendritic Cell Lymphoma
- Update on the Psoriasis Treatment by Biologics and Standard Systemic Drugs
- Patiens with Primary Lymphoedema Followed in the Lymphology Center of the Department of Dermatology of the 2nd Medical School and Bulovka University Hospital in the Years 2000–2006